Stay updated on Biomarker Response to Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-02T13:22:46.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    A banner announces NIH website updates and says NIH content may use “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-26T13:48:29.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T13:47:56.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changed from v3.7.0 to v3.7.1; the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T14:06:23.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with site header/navigation, indicating access is blocked rather than showing the study record. This reflects an access-control issue rather than a substantive update to the content.
    Difference
    19%
    Check dated 2026-09-21T22:57:37.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.5 to v3.6.6, representing a minor update to the page version. No changes to the displayed study content or details are indicated.
    Difference
    0.0%
    Check dated 2026-08-31T17:40:41.000Z thumbnail image

Stay in the know with updates to Biomarker Response to Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.